Abstract 3443
Background
Breast cancer is the most common cancer in women. Most breast tumors are ER(+)/hormone-dependent, this makes it possible to treat them with tamoxifen and other SERM/SERD drugs. Combination treatment of tamoxifen with novel drugs provides an efficient way for reduction of the drug concentration. The aim of the work was to obtain novel less toxic oligomycin derivatives for combinatorial treatment with tamoxifen.
Methods
Oligomycin A was produced at BIOAN (Moscow, Russia) using Streptomyces avermitilis NIC B62. The oligomycin derivatives were synthesized from oligomycin A. MCF-7 breast cancer cell line and MCF-10A human mammary epithelial cell line were obtained from the ATCC collection. Hormone-resistant subline was developed by long-term treatment of MCF-7 line with tamoxifen. Antiproliferative activity was measured by MTT.
Results
A series of less toxic oligomycin A derivatives, selectively modified at the C-33 position of the side chain, was synthesized, and their activity against hormone-dependent breast cancer cells was tested. Lead compound, a (33S)-diastereomer of oligomycin A (epi-oligomycin A), was chosen, which showed high activity towards MCF-7 breast cancer cells and MCF-7/TR hormone-resistant cells. Low doses of tamoxifen and epi-oligomycin A, which had no significant effects on the growth of MCF-7 cells, were evaluated. In combination, low doses of tamoxifen and epi-oligomycin A caused a significant antiproliferative effects on MCF-7 cells. Moreover, it was possible to return the sensitivity of hormone-resistant subline to tamoxifen by epi-oligomycin A treatment. Non-malignant epithelial cells, MCF-10A, were less sensitive to epi-oligomycin A.
Conclusions
Novel epi-oligomycin A enhances response to tamoxifen, which allows for reduction of the effective drug concentration. Combinatorial strategy with epi-oligomycin A may hold promise in development of therapies against breast tumours, including those with acquired resistance to the hormonal treatment. The research is supported by Russian Science Foundation (chemistry, agreement 15-15-00141) and the Russian Foundation for Basic Research (biology, 18-015-00422).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Russian Science Foundation (chemistry, agreement 15-15-00141) and the Russian Foundation for Basic Research (biology, 18-015-00422).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4852 - Impact of routine screening and preemptive treatment on hepatitis B virus reactivation (HBVr) in patients receiving chemotherapy
Presenter: Celine Marty
Session: Poster Display session 1
Resources:
Abstract
5225 - The uptake, patient satisfaction and efficacy of scalp cooling among patients receiving chemotherapy in an Irish oncology day ward.
Presenter: William Maher
Session: Poster Display session 1
Resources:
Abstract
1901 - Placebo adverse events (AEs) in targeted and immune cancer therapy in the adjuvant and advanced setting: A systematic review and meta-analysis
Presenter: Diego Enrico
Session: Poster Display session 1
Resources:
Abstract
3258 - Reduced antibody levels and high seronegativity rates against vaccine preventable diseases pose a risk factor for infections in patients with solid and hematologic cancers
Presenter: Angela Guzek
Session: Poster Display session 1
Resources:
Abstract
3211 - Prognostic Factors Influencing Outcome After Therapy With Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin's Lymphoma
Presenter: Veselina Goranova - Marinova
Session: Poster Display session 1
Resources:
Abstract
4949 - Phase I Study of CC-90010 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
Presenter: Victor Moreno
Session: Poster Display session 1
Resources:
Abstract
2271 - Pretreatment coagulation factors related to prognosis in patients with natural killer/T cell lymphoma
Presenter: Yue Chai
Session: Poster Display session 1
Resources:
Abstract
4335 - Diffuse large B cell lymphoma in the elderly. A retrospective analysis of standard versus alternative treatments
Presenter: Irene Sillero
Session: Poster Display session 1
Resources:
Abstract
5117 - MIPI as a superior prognostic tool in Mantle Cell Lymphoma compared to monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratios
Presenter: Filipa Macedo
Session: Poster Display session 1
Resources:
Abstract
5135 - Dose adjustment of chemotherapy in aggressive lymphoma using automated and standardized analysis and evaluation of DNA double strand breaks
Presenter: Julia Schröder
Session: Poster Display session 1
Resources:
Abstract